- IRRAflow Intraventricular Hemorrhage (IVH) Case Report
Published in Cureus Journal of Medical Science
- Publication also documents the ability to deliver targeted
thrombolytic medication via IRRAflow's recurring irrigation for the
first time in peer-reviewed scientific literature
STOCKHOLM, May 28, 2021 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced the publication of a clinical case report entitled,
"Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult
Intraventricular Hemorrhage Using IRRAflow Self-Irrigating
Catheter" in the Cureus Journal of Medical Science.1
The publication concluded that the use of IRRAflow is a
"safe and effective way to avoid complications related to standard
EVD placement, such as clotting and replacement." Also, it was
noted that "our case demonstrates clear radiographic and clinical
superiority of the IRRAflow system compared to standard
EVD."
This manuscript reports the use of IRRAflow to treat
intraventricular hemorrhage (IVH) for the first time in
peer-reviewed literature. In addition, the case report also
documents the initial published clinical experience using the
IRRAflow system to deliver medication that dissolves blood
collected within the ventricles after a hemorrhagic stroke.
Previously, targeted delivery of anti-spasm medication using an
earlier generation of the IRRAflow system was reported in
the Asian Journal of Neurosurgery.2
"Documenting the treatment of an IVH with IRRAflow for
the first time in a peer-reviewed journal is a meaningful step
forward in our efforts to build clinical evidence to support the
system's front-line use," said Kleanthis G.
Xanthopoulos, Ph.D., Chief Executive Officer of IRRAS. "Even
more importantly, when a world-leading institution such as Buffalo
General Medical Center highlights clearly superior performance of
IRRAflow compared to passive drainage techniques, it
validates the system's impact and sets the stage for broadened
adoption."
The corresponding author on the report is Dr. Adnan Siddiqui, MD, Vice Chairman and Professor
of Neurosurgery at the State University of New
York at Buffalo (UB) Jacobs School of Medicine and
Biomedical Sciences. Dr. Siddiqui is also the director of
neurosurgical stroke service at Kaleida Health's Gates Vascular
Institute (GVI), director of the neuroendovascular fellowship
program at UB, director of the UB Canon Stroke and Vascular
Research Center, and the Chief Executive Officer & Chief
Medical Officer of the Jacobs Institute (JI), a non-profit medical
device innovation center.
Dr. Elad Levy, MD, Chairman of
the Department of Neurosurgical Surgery at the UB Jacobs School of
Medicine and Biomedical Sciences and Secretary of the Congress of
Neurological Surgeons (CNS) Executive Committee, served as a
co-author on the case report, along with Dr. Timothy O'Connor, MD, Dr. Ryan Hess, MD, Dr. Asham
Khan, MD, and Dr. Kenan
Rajjoub, MD.
The case report highlights treatment using the IRRAflow
fluid management system for a patient suffering from IVH at Buffalo
General Medical Center in Buffalo,
NY. IVH is a devastating form of intracranial bleeding "with
an expected mortality rate between 50 and 80%," according to the
case report.
During this patient treatment, an IRRAflow catheter was
placed into the patient's right ventricle and provided drainage
without interruption throughout patient treatment. A traditional
external ventricular drain (EVD) was placed in the patient's left
ventricle, but, "by the following day, the left-sided EVD catheter
had become clotted and stopped draining." The occluded EVD was
subsequently replaced with a second IRRAflow catheter, and
the decision was made to deliver a thrombolytic medication,
alteplase, through the IRRAflow catheter to dissolve the
collected blood. After this decision to convert treatment
completely to IRRAflow, follow-up scans clearly showed a
decrease in the volume of blood present and the size of the
patient's enlarged ventricles, which was not possible before with
an occluded EVD.
"Our long-term strategy is to expand the use of IRRAflow
toward targeted drug delivery," said Will
Martin, President and Chief Commercial Officer of IRRAS.
"With traditional IV administration, it is difficult for many of
these medications to cross into the brain and reach therapeutic
levels, but IRRAflow's recurring irrigation can potentially
offer this capability in a controlled manner. Documenting this
early experience in published literature sets the stage for future
conversations with regulatory agencies."
1 Rajjoub K, Hess R M, O'Connor T E,
et al. (May 22, 2021) Drainage,
Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult
Intraventricular Hemorrhage Using IRRAflow® Self-Irrigating
Catheter. Cureus 13(5): e15167. doi:10.7759/cureus.15167
2 Venkataramana NK, Rao SA, Naik AL, Shetty
K, Murthy P, Bansal A, Panotopoulos C. Innovative approach for
prevention and treatment of post subarachnoid hemorrhage vasospasm:
A preliminary report. Asian J Neurosurg 2012; 7: 78-80.
About IRRAS
IRRAS is a global medical care company focused on innovative
medical solutions to improve the lives of critically ill patients.
IRRAS designs, develops, and commercializes neurocritical care
products that transform patient outcomes and decrease the overall
cost of care by addressing complications associated with current
treatment methodologies. IRRAS markets and sells its comprehensive,
innovative IRRAflow and Hummingbird ICP Monitoring product
lines to hospitals worldwide through its direct sales organization
in the United States and select
European countries as well as an international network of
distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker:
IRRAS).
For more information, please contact:
Sten Gustafsson
IR
sten.gustafsson@irras.com
+46 102 11 5172
The information was released for public disclosure, through
the agency of the contact person above, on May 28, 2021 at 08:30 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-announces-publication-of-a-case-report-from-buffalo-general-medical-center-highlights-clinical,c3355581
